Clinical trial of personalized cancer vaccine demonstrates feasibility, safety, immune activation
by Harvard University edited by Gaby Clark, reviewed by Robert Egan The personalized biomaterial-based cancer vaccine consists of a porous biomaterial scaffold the size of an aspirin tablet that is infused with immune cell-recruiting and activating molecules and inactivated tumor antigens derived from tumors of the trial participants. Credit: Wyss Institute at Harvard University The first-in-human clinical phase […]
